Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1296-1305

  Ward, Christopher S ^a   Venkatesh, Humsa S ^a   Chaumeil, Myriam M ^a   Brandes, Alissa H ^a   VanCriekinge, Mark ^a   Dafni, Hagit ^a   Sukumar, Subramaniam ^a   Nelson, Sarah J ^a   Vigneron, Daniel B ^a   Kurhanewicz, John ^a   James, C David ^b   Haas Kogan, Daphne A ^b   Ronen, Sabrina M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTIC ACID; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PYRUVIC ACID;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CARBON NUCLEAR MAGNETIC RESONANCE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HYPERPOLARIZATION; LACTATE BLOOD LEVEL; MODULATION; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARBON ISOTOPES; CHROMONES; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MONITORING, PHYSIOLOGIC; MORPHOLINES; NEOPLASMS; SIROLIMUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76749161366     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2251     Document Type: Article

References (50)

1. Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 2001;3:304-12.
2. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004;90: 2-8.
3. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
4. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
5. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
6. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003;10:207-13.
7. Workman P, Clarke PA, Guillard S, Raynaud FI. Drugging the PI3 kinome. Nat Biotechnol 2006;24:794-6.
8. Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p110σ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006; 25:6648-59.
9. Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and anti-angiogenic activity. Cancer Res 2008;68:206-15.
10. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 2008;27:5416-30.
11. Chakravarti A, Palanichamy K. Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res 2008;139:173-89.
12. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008;8:393-412.
13. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-24.
14. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999;10:159-64.
15. 31P MRS of experimental tumours. NMR Biomed 1993;6: 345-65.
16. Evelhoch JL, Gillies RJ, Karczmar GS, et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000;2: 152-65.
17. 31P measurements of response to treatment. NMR Biomed 1998;11:314-40.
18. Vigneron D, Bollen A, McDermott M, et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging 2001;19:89-101.
19. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001;84:691-6.
20. Chung YL, Troy H, Banerji U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003;95:1624-33.
21. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res 2005;65:3356-63.
22. Beloueche-Babari M, Jackson LE, Al-Saffar NM, et al. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther 2006;5:187-96.
23. Koul D, Shen R, Kondo Y, et al. Cellular and in vivo activity of a novel PI3K inhibitor PX-866 for treatment of human glioblastoma. Neurooncol. In press 2010.
24. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003;100:10158-63.
25. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006;66:10855-60.
26. 13C-1-pyruvate. Magn Reson Med 2007;58:65-9.
27. 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13:1382-7.
28. Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med 2007;58:1099-106.
29. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008;68:8607-15.
30. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
31. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82.
32. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757-63.
33. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;277:27975-81.
34. Arsham AM, Plas DR, Thompson CB, Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 α nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 2002;277:15162-70.
35. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-26.
36. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 1995;270:21021-7.
37. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441: 437-43.
38. 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta 1991;1095:5-16.
39. Brindle KM. NMR methods for measuring enzyme kinetics in vivo. Prog Nucl Magn Reson Spectrosc 1988;20:257-93.
40. Vassault A. Lactate dehydrogenase. Methods Enzymatic Anal 1983;3.
41. Bernofsky C, Swan M. An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem 1973;53:452-8.
42. 13C MR metabolic imaging: application to brain tumors. Neuro-oncol. In press 2010.
43. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001;31:269-86.
44. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003;2:497-507.
45. Bhujwalla ZM, Glickson JD. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int J Radiat Oncol Biol Phys 1996;36:635-9.
46. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21: 3995-4004.
47. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12:363-9.
48. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9: 2416-25.
49. Glunde K, Shah T, Winnard PT, Jr., et al. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1α signaling in a human prostate cancer model. Cancer Res 2008;68:172-80.
50. 1H decoupling. J Magn Reson 2009; 197:100-6.